The Use of Targeted Agents in the Treatment of Gynecologic Cancers

Shaina F. Bruce; Matthew A. Powell

doi:10.1007/s11864-021-00918-0

The Use of Targeted Agents in the Treatment of Gynecologic Cancers

Shaina F. Bruce, Matthew A. Powell

Research output: Contribution to journal › Review article › peer-review

3 Scopus citations

Abstract

Patients with advanced and recurrent ovarian, uterine, and cervical cancers have limited efficacious treatment options and poor outcomes. The development of agents that target DNA repair mechanisms, angiogenesis, immune checkpoints, and hormone receptor expression provides additional options for these patients. Many available targeted therapies have limited efficacy as single agents, so clinical trials investigating combination therapies as well as continued identification and validation of predictive biomarkers are critical. Many novel small molecule therapies, antibody drug conjugates, and therapeutic vaccines are also in development. This review will focus on recent evidence supporting the use of clinically available targeted therapies for gynecologic cancer.

Original language	English
Pages (from-to)	15-28
Number of pages	14
Journal	Current treatment options in oncology
Volume	23
Issue number	1
DOIs	https://doi.org/10.1007/s11864-021-00918-0
State	Published - Jan 2022

Keywords

Anti-angiogenics
Gynecologic cancer
Hormonal therapy
Immunotherapy
PARP inhibitor
Targeted therapy

Access to Document

10.1007/s11864-021-00918-0

Cite this

@article{f0858f679deb464da8e6441b53ca4035,

title = "The Use of Targeted Agents in the Treatment of Gynecologic Cancers",

abstract = "Patients with advanced and recurrent ovarian, uterine, and cervical cancers have limited efficacious treatment options and poor outcomes. The development of agents that target DNA repair mechanisms, angiogenesis, immune checkpoints, and hormone receptor expression provides additional options for these patients. Many available targeted therapies have limited efficacy as single agents, so clinical trials investigating combination therapies as well as continued identification and validation of predictive biomarkers are critical. Many novel small molecule therapies, antibody drug conjugates, and therapeutic vaccines are also in development. This review will focus on recent evidence supporting the use of clinically available targeted therapies for gynecologic cancer.",

keywords = "Anti-angiogenics, Gynecologic cancer, Hormonal therapy, Immunotherapy, PARP inhibitor, Targeted therapy",

author = "Bruce, {Shaina F.} and Powell, {Matthew A.}",

note = "Publisher Copyright: {\textcopyright} 2022, The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.",

year = "2022",

month = jan,

doi = "10.1007/s11864-021-00918-0",

language = "English",

volume = "23",

pages = "15--28",

journal = "Current treatment options in oncology",

issn = "1527-2729",

number = "1",

}

TY - JOUR

T1 - The Use of Targeted Agents in the Treatment of Gynecologic Cancers

AU - Bruce, Shaina F.

AU - Powell, Matthew A.

PY - 2022/1

Y1 - 2022/1

N2 - Patients with advanced and recurrent ovarian, uterine, and cervical cancers have limited efficacious treatment options and poor outcomes. The development of agents that target DNA repair mechanisms, angiogenesis, immune checkpoints, and hormone receptor expression provides additional options for these patients. Many available targeted therapies have limited efficacy as single agents, so clinical trials investigating combination therapies as well as continued identification and validation of predictive biomarkers are critical. Many novel small molecule therapies, antibody drug conjugates, and therapeutic vaccines are also in development. This review will focus on recent evidence supporting the use of clinically available targeted therapies for gynecologic cancer.

AB - Patients with advanced and recurrent ovarian, uterine, and cervical cancers have limited efficacious treatment options and poor outcomes. The development of agents that target DNA repair mechanisms, angiogenesis, immune checkpoints, and hormone receptor expression provides additional options for these patients. Many available targeted therapies have limited efficacy as single agents, so clinical trials investigating combination therapies as well as continued identification and validation of predictive biomarkers are critical. Many novel small molecule therapies, antibody drug conjugates, and therapeutic vaccines are also in development. This review will focus on recent evidence supporting the use of clinically available targeted therapies for gynecologic cancer.

KW - Anti-angiogenics

KW - Gynecologic cancer

KW - Hormonal therapy

KW - Immunotherapy

KW - PARP inhibitor

KW - Targeted therapy

UR - http://www.scopus.com/inward/record.url?scp=85124977757&partnerID=8YFLogxK

U2 - 10.1007/s11864-021-00918-0

DO - 10.1007/s11864-021-00918-0

M3 - Review article

C2 - 35167006

AN - SCOPUS:85124977757

SN - 1527-2729

VL - 23

SP - 15

EP - 28

JO - Current treatment options in oncology

JF - Current treatment options in oncology

IS - 1

ER -

The Use of Targeted Agents in the Treatment of Gynecologic Cancers

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this